DrugPatentWatch Database Preview

SANCUSO Drug Profile

« Back to Dashboard

When do Sancuso patents expire, and what generic alternatives are available?

Sancuso is a drug marketed by Kyowa Kirin and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in thirty-one countries.

The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the granisetron profile page.

Summary for SANCUSO

International Patents:	40
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	32
Clinical Trials:	15
Patent Applications:	4,063
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SANCUSO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SANCUSO
DailyMed Link:	SANCUSO at DailyMed

Pharmacology for SANCUSO

Drug Class	Serotonin-3 Receptor Antagonist
Mechanism of Action	Serotonin 3 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for SANCUSO

Antiemetics

Serotonin Antagonists

Synonyms for SANCUSO

1-Methyl-1H-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide

1-METHYL-N-((1R,3R,5S)-9-METHYL-9-AZABICYCLO[3.3.1]NONAN-3-YL)-1H-INDAZOLE-3-CARBOXAMIDE

1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide

1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide

1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide

1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide

1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide

1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide

107007-99-8 (mono-hydrochloride)

109889-09-0

121061-98-1

124998-65-8

1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-

1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-[(3-ENDO)-9-METHYL-9-AZABICYCLO[3.3.1]NON-3-YL]-

3702AH

889g090

A802101

AB00918713-07

AB07494

AC-8910

AC1NR4P1

AKOS025402424

AN-7538

APF 530

APF530

API0005490

BDBM50443668

BDBM50449636

BIDD:GT0272

BRL 43694

BRL 43964

BRL-43694

C07023

CCG-221158

CHEBI:5537

CHEBI:94501

CHEMBL1290003

D04370

D0J5KF

DB00889

DL-166

DTXSID0023111

ENDO-GRANISETRON

FT-0626805

GRANESETRON

granisetron

Granisetron (JAN/USAN/INN)

Granisetron (USAN/INN)

Granisetron [USAN:INN:BAN:JAN]

Granisetron Monohydrochloride

Granisetronum

GTPL2300

HMS2089P14

Kevatril

Kevatril|||1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide,

Kytril (TN)

Q-101870

Sancuso (TN)

SCHEMBL34178

SCHEMBL4890

SCHEMBL4891

Sustol

UNII-WZG3J2MCOL

VA11035

W-5139

WZG3J2MCOL

ZINC100018852

ZINC100018854

ZINC347

US Patents and Regulatory Information for SANCUSO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kyowa Kirin	SANCUSO	granisetron	FILM, EXTENDED RELEASE;TRANSDERMAL	022198-001	Sep 12, 2008		RX	Yes	Yes			Y

Paragraph IV (Patent) Challenges for SANCUSO

Drugname	Dosage	Strength	RLD	Date
	Transdermal System	3.1 mg/24 hrs

International Patents for SANCUSO

Country	Document Number	Estimated Expiration
United Kingdom	0302662
Norway	20053663
Japan	4146486
European Patent Office	1589956
Austria	368454
Japan	2006516601
Ukraine	83362